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Prior inhibition of vasoconstrictors normalizes GFR in
postobstructed kidneys
MABEL L. PURKERSON and SAULO KLAHR
Renal Division, Department of Medicine, Washington University School f Medicine, St. Louis, Missouri, USA
Prior inhibition of vasoconstrictors normalizes GFR in postobstructed
kidneys. The present studies were designed to analyze the potential
contribution of angiotensin II and thromboxane A2 to the remarkable
decrease in glomerular filtration rate (GFR) and renal plasma flow
observed after unilateral release of 24-hour bilateral ureteral obstruc-
tion. Pretreatment of the animals with inhibitors of either thromboxane
or angiotensin synthesis for 48 hours prior to and during obstruction
eliminated the contribution of these vasoconstrictors. Inhibition of
these vasoconstrictors during the period of obstruction results in a
greater increase in renal plasma flow and GFR than when inhibition was
accomplished after release of the obstruction. These data suggest a
greater role for these vasoconstrictors in the decrease in GFR that
occurs with obstruction. Simultaneous inhibition of thromboxane and
angiotensin production normalized OFR of the postobstructed kidney.
Administration of atrial peptide after release of obstruction in the
different groups of rats resulted in further increases in GFR, urine flow
and absolute sodium excretion. It is suggested that atrial peptide
participates in the renal hemodynamic changes that occur in the
postobstructed kidney.
Ureteral obstruction decreases glomerular filtration rate
(GFR) in dogs, rabbits and rats [1—31. The mechanisms under-
lying the decrease of GFR in this setting are not completely
understood. After the onset of ureteral obstruction, the aug-
mented intraureteral pressure is transmitted to the tubules,
leading to increased intratubular pressure without a comparable
change in intraglomerular capillary hydrostatic pressure, result-
ing in a decrease in net filtration pressure across the glomerular
capillary wall. This may be the major factor responsible for the
decrement in GFR in the first few hours of obstruction [3—5].
Twenty-four hours after onset of obstruction, proximal intratu-
bular pressure is decreased, compared to values observed after
one hour of obstruction, but in animals with bilateral ureteral
obstruction intratubular pressure is still greater than preob-
struction values. At this time, both renal plasma flow and
intraglomerular capillary pressure are decreased [3, 5]. The
decrement in intraglomerular capillary pressure, Ps,, observed
after obstruction of 24 hours duration, accounts for most of the
fall in net filtration pressure (zIP) and single nephron GFR at this
time interval. The decrease in total renal plasma flow, due in
part to afferent and probably efferent arteriolar vasoconstric-
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tion, is accompanied by a fall in plasma flow per nephron (QA),
which contributes to the decrease in GFR.
Two major vasoconstrictors, angiotensin II and thromboxane
A, have an important role in the marked decrease of plasma
flow per nephron and single nephron GFR seen in obstruction.
Inhibition of thromboxane A2 synthesis after release of ureteral
obstruction in rats leads to an increase in plasma flow per
nephron as a consequence of a decrease in afferent and efferent
arteriolar vasoconstriction [6]. Infusion of angiotensin II into
normal animals increases net filtration pressure, presumably
due to greater vasoconstriction of the efferent arteriole than the
afferent arteriole. Inhibition of angiotensin II synthesis after
relief of obstruction increases GFR [7].
Most of the studies designed to examine the role of increased
synthesis of thromboxane and angiotensin II on renal function
of the postobstructed kidney have utilized blockade of produc-
tion of these two vasoconstrictors after release of obstruction of
24 hours duration [6—9]. In the present experiments, we have
analyzed the potential contribution of angiotensin II and throm-
boxane A2 to the marked decrease in GFR and renal plasma
flow that is observed after unilateral release of bilateral ureteral
obstruction of 24 hours duration by pretreating the animals for
48 hours preceding the onset of obstruction with inhibitors of
angiotensin converting enzyme (ACE) and/or inhibitors of
thromboxane synthesis. As compared to the results of experi-
ments in which synthesis of angiotensin II and thromboxane A2
was blocked after release of obstruction of 24 hours duration,
the results of this study indicate that pretreatment with inhibi-
tors of angiotensin It and/or thromboxane A2 synthesis results
in a substantially greater increase in renal plasma flow and GFR
than when inhibition is attempted after release of the obstruc-
tion. Thus, the results of the present experiments indicate that
the quantitative contribution of thromboxane A2 and angioten-
sin II to the alterations in renal function that occur in obstruc-
tion are much greater than inferred from data obtained in
studies in which inhibition of these substances was accom-
plished after release of obstruction,
Atrial peptide has been found to be elevated in rats with
bilateral ureteral ligation but not in rats with unilateral ureteral
ligation [101. To assess the potential contribution of atrial
peptide to the hemodynamic changes seen after release of
obstruction, we also examined the effects of exogenous atrial
peptide administration on renal plasma flow and GFR after
release of obstruction in rats in which angiotensin II and/or
1306
Purkerson and Klahr: Vasoconstric for and GFR inhibition in obstruction 1307
Table 1. Different groups of rats studied
Control rats (two normal kidneys)
No pretreatment (Group I, N = 14)
Pretreatment with OKY-046 (Group II, N = 5)
Pretreatment with Enalapril (Group lii, N = 5)
Rats with unilateral release of bilateral ureteral obstruction
No pretreatment (Group 1. N = 31)
Atrial peptide administered after baseline clearances (Group IA,
N= II)
OKY-046 administered after baseline clearances (Group lB.
N =8)
Enalapril administered after baseline clearances (Group IC,
N = 12)
Pretreatment with OKY-046 (Group II, N = 6)
Pretreatment with Enalapril (Group Ill, N = 6)
Pretreatment with both Enalapril and OKY-046 (Group IV,N=6)
thromboxane synthesis was or was not inhibited prior to
obstruction.
Methods
Experiments were performed in 73 female Sprague-Dawley
rats weighing 250 to 330 grams. The rats were fed a standard rat
chow containing 22.8% protein (Purina Lab Chow, Ralston-
Purina Company, St. Louis, Missouri, USA) and allowed tap
water ad libitum. Twenty-four rats were normal controls. In 49
animals, under light ether anesthesia, both ureters were ex-
posed through a midline abdominal incision and ligated with 2-0
silk. The animals did not receive food or water from the time of
ureteral ligation until the time clearance studies were per-
formed.
Clearance studies
In normal rats, under light ether anesthesia cannulas were
placed in the tail vein, femoral artery and bladder. Animals
were allowed to recover from anesthesia before clearance
studies were done in the awake state (see below). Rats with
bilateral ureteral obstruction of 24 hours duration were anes-
thetized with ether for a brief period while cannulas were placed
in the tail vein, femoral artery and ureter in preparation for the
experiments. Only one ureter was cannulated proximal to the
ligature placed 24 hours earlier (unilateral release of bilateral
ureteral obstruction). Rats were placed in Plexiglas holders, and
a period of three hours was allowed for recovery from anesthe-
sia and for urine flow to become stable, A priming dose of
chemical inulin (Fisher Company, St. Louis, Missouri, USA),
designed to produce plasma levels of 75 to 100 mg/dl and
chemical para-aminohippurate (PAH; Merck, Sharp & Dohme,
West Point, Pennsylvania, USA) calculated to produce plasma
levels of I to 2 mg/dl were infused in 0.6 ml of normal saline
over a three minute period. This was followed by a sustaining
infusion delivered at 49 .d/min, which contained sufficient inulin
and PAH to maintain plasma levels of these compounds.
Following an equilibration period of at least 60 minutes, and
approximately four hours after release of ureteral obstruction,
three consecutive collections of urine and blood were made for
estimation of GFR by inulin clearance, renal plasma flow (RPF)
by PAH clearance (CPAH) and urinary excretion of sodium and
water.
The different experimental groups studied are summarized in
Table I. Three groups of control rats were studied. The first
control group (N = 14) received no prior treatment before
clearance studies. Rats of control group II (N = 5) received an
inhibitor of thromboxane synthesis (OKY-046) which was dis-
solved in saline and was administered for two days prior to
clearance studies at a dose of 20 mg/kg body weight, s.c., twice
daily. Rats of control group III (N = 5) received an oral dose of
an inhibitor of the angiotensin converting enzyme for two days
prior to and on the day of clearance studies. Four groups of rats
with bilateral ureteral obstruction (BUO) were studied (Table
I). In group I (N = 31) no pretreatment was given prior to
bilateral ureteral obstruction. After release of obstruction these
animals had clearance studies performed in the awake state. In
group IA (N = 11) after three baseline clearance periods the
animals received a continuous infusion of atrial peptide (atrio-
peptin I to 24 or AP 1-24, Lot SL2, Searle Company, Skokie,
Illinois, USA) at a rate of 17.4 pg/kg body wt/hr. Three urine
collection periods were obtained. These collections were begun
20 minutes after AP infusion was initiated. Upon completion of
these studies, the AP infusion was discontinued and three
additional urine samples were collected. In group lB (N = 8)
after three control clearance periods OKY-046 was given at an
i.v. dose of 2 sg/kg body wt/hr and three additional clearance
periods were obtained. In group IC after performing three
clearance periods Enalaprilat at a dose of 50 .tg/kg body wt/hr
was given i.v. and collection of three additional clearance
periods were initiated 20 minutes after the administration of the
drug. A protocol similar to that of group IA was used in animals
of group II, III and IV with bilateral ureteral obstruction. Rats
of group II (N = 6) received OKY-046 subcutaneously for two
days prior to obstruction, at a dose of 20 mg/kg body wt twice
daily. Animals also received the inhibitor of thromboxane
synthesis on the day the obstruction was performed and the
morning when the obstruction was released. Animals in group
III (N = 6) received Enalapril maleate, 5 mg/kg body wt, by
gastric gavage twice daily for two days prior to obstruction.
They also received 5 mg/kg p.o. on the day of the obstruction.
After release of the obstruction, Enalaprilat 50 pg/kg body wt/
hr was administered. In a fourth group of animals (N = 6), both
Enalapril maleate, the ACE inhibitor, and OKY-046, an inhib-
itor of thromboxane synthesis were given concommitantly, as
described above.
Results
Figure 1 shows the results of inulin clearances in control rats
that did not receive treatment, in control rats pretreated with an
inhibitor of thromboxane synthesis or an inhibitor of the ACE
for two days prior to clearance studies. Inulin clearance values
for one kidney averaged 5.82 0.20 mI/mm/kg body wt in
untreated control rats; 6.53 0.44mI/mm kg body wt in control
rats pretreated with OKY-046 and 6.56 0.62 mI/mm kg body
wt in control rats pretreated with Enalapril. These values were
not significantly different from each other, although both pre-
treated groups had inulin clearance values that were 12.2 and
12.7% greater than the values obtained in control rats not
pretreated with inhibitors of the two vasoconstrictors.
Table 2 shows the results of clearance studies after unilateral
release of bilateral ureteral obstruction in rats of group IA.
Baseline inulin clearance in these rats averaged 1.54 ml/
mm/kg body wt. The mean inulin clearance uncorrected for
weight was 0.46 mI/mm. These values are approximately
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Fig. 1. Mean insulin clearance values in three groups of normal rats.
Normal rats with no treatment (Group I, N = 14): normal rats receiving
OKY-046, an inhibitor of thromboxane synthesis, for two days prior to
clearance studies (Group 11, N = 5); normal rats receiving an inhibitor
of the angiotensin converting enzyme for two days prior to clearance
studies (Group III, N = 5). Clearance values were measured for both
kidneys from bladder urine. The data presented here are for one kidney
and assume that the function of the two kidneys is identical in normal
rats. Expressing the clearance values per kidney allows comparison
with the data obtained after unilateral release of bilateral ureteral
obstruction. Mean inulin values for rats pretreated with OKY-046 or
enalapril are not significantly different from mean Cir, values obtained in
normal untreated rats (P = 0.165 and P = 0.271, respectively).
one-third to one-fourth of the values obtained in a single kidney
of normal rats of comparable size and weight (Fig. 1). Conse-
quently, as previously reported, 24 hour obstruction of the
urinary tract results, even after release of the obstruction, in a
remarkable decrease in GFR [11, 12]. The postobstructed
kidney also exhibited a marked increase in both fractional
sodium and water excretion. Following the administration of
atrial peptide, there were significant increases in urine flow,
inulin and PAH clearances, absolute and fractional sodium
excretion and fractional water excretion. Discontinuation of the
infusion of atrial peptide (recovery) resulted in significant
decreases in urine flow, absolute and fractional sodium excre-
tion and fractional water excretion. Although there was a
decrease in both inulin and PAH clearances, this decrease did
not achieve statistical significance.
Table 3 presents the clearance values for rats of groups lB
and IC. Acute administration of OKY-046 or Enalapril after
unilateral release of bilateral ureteral obstruction resulted in a
significant increase in the clearances of both inulin and PAH.
Inulin and PAH clearances, as compared to baseline clearance
values, increased by 28.9% and 21.4%, respectively, after the
administration of the inhibitor of thromboxane synthesis. Acute
administration of the ACE inhibitor increased mean inulin
clearance by 50.3% and CPAH by 38.7%,
Table 4 presents the clearance data in rats pretreated with
OKY-046, an inhibitor of thromboxane synthesis, for two days
prior to obstruction (group II). Of note is the fact that both
inulin and PAH clearance values were greater in this group of
rats than in animals of group I (IA, lB or IC). Values for urine
flow, absolute sodium excretion, fractional sodium excretion
and fractional water excretion were somewhat less in these
animals than in rats of group IA. On the other hand, the infusion
of atrial peptide in rats of group II resulted in similar changes to
those observed in animals of group IA. There were significant
increases in urine flow, inulin clearance, absolute sodium
excretion and the fractional excretion of both sodium and
water. Although there was a numerical increase in the clearance
of PAH, this increase did not achieve statistical significance.
The results of studies conducted in rats that were pretreated
with Enalapril for two days prior to the onset of bilateral
ureteral obstruction (group III) are shown in Table 5.Of note is
the fact that in the basal state these animals had a considerable
increase in urine flow as compared to rats in groups IA and II.
The baseline clearances of inulin and PAH were also higher
than the values observed in rats of groups (IA, lB or IC) and II.
Absolute and fractional sodium excretion, and fractional water
excretion were markedly increased as compared to values
obtained in groups I and II. Despite the marked increase in
inulin clearance and sodium excretion in the baseline periods,
the infusion of atrial peptide resulted in a further increase in
these values. There was a significant increase in urine flow and
inulin clearance with atrial peptide administration. The clear-
ance of PAH rose, but the increase was not statistically
significant. There was a marked increase in absolute sodium
excretion with modest changes in fractional sodium and frac-
tional water excretion. Most of the increase in absolute sodium
excretion observed seemed to correlate with a marked increase
in the filtered load of sodium, due to an increase in glomerular
filtration rate. Discontinuation of atrial peptide infusion resulted
in decreases in urine flow, inulin clearance, and the absolute
and fractional excretion of both sodium and water.
When both OKY-046 and Enalapril were administered for
two days prior to obstruction, there was a marked increase in
inulin clearance and urine flow after release of obstruction as
shown for rats of group IV in Table 6. Again, when compared to
rats of groups I and II, these rats exhibited a marked increase in
urine flow, inulin clearance, absolute sodium excretion and
fractional excretion of sodium and water. It is of note that inulin
clearance was greater in this group of rats than in those of the
preceding three groups. The data suggest that the effects of
thromboxane inhibitors and angiotensin-converting enzyme in-
hibitors on GFR of the postobstructed kidney may be additive.
Administration of atrial peptide in these animals resulted in
8
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Table 2. Clearance data in rats in group IA: No pretreatment, acute administration of atrial peptide
.Period
v
pJ/min
Ci,AH UNaV
sEq/min
FEN FEH,o
%mi/mm kg body vt
-
Baseline 75,5 13.5 1.54 0.15 8.17 1.2 8.92 1.67 15.7 3.4 18.6 4.0
Atrial Peptide 202.9 31.9 2.96 0.42 11.54 1.4 26.54 4.02 26.1 4.9 27.4 5.3
Recovery 117.5 23.6 2.23 0.27 9.64 1.34 15.71 3.33 19.8 4.7 20.7 4.8
P (Baseline vs. atrial peptide) <0.001 <0.00 1 <0.001 <0.001 <0.001 <0.006
P (Atrial peptide vs. recovery) <0.001 <0.0 13 <0.0 19 <0.001 <0.005 <0.003
Values are mean standard error of the mean in II rats. Each period is the average of three clearance collections in each of eleven rats.
Abbreviations are: V. urine flow; C, inulin clearance; CPAH, clearance of para-aminohippurate; UNV, absolute sodium excretion; FENa,
fractional sodium excretion; FEH,o, fractional water excretion. Recovery refers to the discontinuation of atrial peptide infusion.
Table 3. Clearance data in rats of groups lB and IC: No pretreatment, acute administration of 0KY-046 or enalapril
Period
y
.d/min
Cp UNAV
sEq/min
FENa FEH,o
%mi/mm/kg body ui
Group lB (OKY-046)
Baseline 43.0 4.0 1.52 0.17 7.65 0.59 3.98 0.40 8.4 1.2 12.9 1.5
OKY-046 49.6 4.0 1.96 0.20 9.29 0.47 4.77 0.55 7.7 1.3 11.6 1.7
P (baseline vs. OKY-046) <0.0 19 <0.001 <0.001 <0.026 >0.07 <0.03
Group IC (Enalapril)
Baseline 43.6 5.9 1.51 0.17 7.67 1.08 4.61 0.74 8.7 2.2 11.5 2.8
Enalapril 61.2 6.0 2.27 0.23 10.64 1.40 7.47 0.63 9.0 2.1 10.9 2.8
P (baseline vs. Enalapril) <0.001 <0.001 <0.001 <0.001 >0.637 >0.521
Values are mean standard error of the mean in 8 rats (Group I B) and in 12 rats (Group IC). After 3 clearance baseline periods rats were given
either an inhibitor or thromboxane synthesis (OKY-046) or an inhibitor of the angiotensin-converting enzyme (Enalapril). Abbreviations used as
in Table 2.
Table 4. Clearance data in rats of group 11: OKY-046 pretreatment
v CPAH UNAV FENa
Period pi/mmn mi/mm/kg body ut p.Eq/mmn
FEH,o
%
Basal 53.0 7.9 2.49 0.49 10.79 1.98 6.02 1.22 7.0 1.6
Atrial peptide 185.7 33.4 4.80 1.16 16.05 4.32 25.43 4.28 16.5 3.9
Recovery 79.0 17.7 3.23 0.73 12.54 2.71 10.60 2.51 8.2 1.8
9.2 2.3
16.2 4.0
9.0 2.3
P (Baseline vs. atrial peptide) <0.007 <0.02 >0.12 <0.003 <0.02
P (Atrial peptide vs. recovery) <0.002 <0.05 >0.19 <0.001 <0.02
<0.03
<0.01
Values are the mean standard error of the mean of 3 clearance periods in each of 6 rats. Abbreviations used as in Table 2.
Table 5. Clearance data in rats of group Ill: Enalapril pretreatment
v Cm CPAH UNAV FENa
Period
.d/min mi/mm/kg body ut p.Eq/min
FEH,o
%
Basal 294.2 53.5 4.41 0.75 15.63 1.12 37.51 6.67 21.4 4.2
Atrial peptide 479.7 84.1 6.22 0.75 18.82 1.05 63.62 11.16 23.2 3.5
Recovery 305.2 71.8 4.94 0.71 18.76 1.40 43.53 9.59 22.2 6.1
25.1 5.1
26,2 4.4
23.2 6.9
P (Basal vs. atrial peptide) <0.003 <0.007 <0.02 <0.003 <0.39
P (Atrial peptide vs. recovery) <0.01 <0.05 >0.96 <0.01 >0.72
<0.60
>0.33
Values are the mean standard error of the mean of 3 clearance collections for each period (basal, atrial peptide infusion and discontinuation
of atrial peptide infusion-recovery) in 6 rats. Abbreviations used as in Table 2.
further increases in urine flow and absolute sodium excretion as
well as fractional salt and water excretion. In contrast to the
other groups, no increase in GFR during infusion of atrial
peptide was observed in these animals.
Basal levels of inulin clearance after unilateral release of
BUO of 24 hours duration in the four groups of rats studied are
shown in Figure 2 for comparison with values obtained in
control (normal) rats (Figure 1). There was a significantly
greater GFR as measured by inulin clearance after release of
obstruction in rats pretreated with OKY-046 or Enalapril as
compared to non-treated rats (group I). When both agents were
administered simultaneously, a further increase in inulin clear-
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Table 6. Clearance data in rats of group IV: Pretreatment with both OKY 0-46 and enalapril
P (Basal vs. atrial peptide) <0.003 <0.7 >0.41 <0.003 <0.39 <0.60
P (Atrial peptide vs. recovery) >0.06 >0.49 >0.44 >0.94 <0.02 <0.03
Values are the mean standard error of the mean of 3 clearance collections for each period (basal, atrial peptide infusion and discontinuation
of atrial peptide infusion—recovery) in 6 rats. Abbreviations used as in Table 2.
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Fig. 2. Baseline levels of inulin clearance in four groups of rats
measured 3 to 4 hours a.t)er unilateral release of bilateral ureteral
obstruction of 24 hours duration. Values for inulin clearance were
significantly greater in rats of group II (pretreated with an inhibitor of
thromboxane synthesis), in rats of group 111 (pretreated with an
inhibitor of angiotensin converting enzyme) and in rats of group IV
(treated with a combination of both a thromboxane synthetase inhibitor
and an inhibitor of angiotensin converting enzyme) as compared to rats
of group I which were untreated. Notice that the values for inulin
clearance in rats of group Ill are significantly higher than those in group
II (P < 0.01), and that the combination of Enalapril and OKY-046
resulted in the highest values of GFR observed after release of
obstruction (group IV).
Atrial peptide
Fig. 3. Levels of mu/in clearance infinir groups ofrats after unilateral
release of bilateral ureteral obstruction of 24 hours duration. These
values were obtained 3 to 4 hours after release of obstruction following
the infusion of atrial peptide (AP) at a rate of 17 zg/min/kg body wt.
Inulin clearance values were significantly higher in rats of groups II, III
and IV as compared to the values observed in rats of group I. Of note
is the fact that the inujin clearance values after AP administration are
significantly greater than the valqes obtained in the basal state prior to
AP administration (Fig. 2). No statistically significant difference in
inulin clearance was observed after administration of AP between rats
of groups II. III and 1V. Notice also that inulin clearance values
following the infusion of AP did not increase as compared to basal
levels (Fig. 2) in rats of group IV (pretreated with a combination of a
thromboxane synthetase inhibitor and an inhibitor of angiotensin con-
verting enzyme).
persisted. Thus, during atrial peptide infusion, inulin clearance
was greater after unilateral release of BUO in animals of groups
II, Ill and IV than in animals of group IA. The highest inulin
clearance after atrial peptide administration (6.22 mI/mini
Period
V
p.1/in in
Ci" Cr,AH
mi/mm/kg body ut
UNAV FEN. FEH,O
p.Eq/min %
Basal 344.0 7.8 5.93 0.53 12.88 0.91 39.38 8.78 15.4 2.6 18.8 3.6
Atrial peptide 514.0 11.5 5.26 0.85 11.77 0.99 56.85 15.38 25.8 4.3 29.2 6.6
Recovery 209.0 58.() 4.80 0.57 11.67 0.85 23.70 3.30 12.0 1.1 14.9 3.0
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ance was noted. The values for inulin clearance after adminis-
tration of atrial peptide in each of the four groups of rats studied
are shown in Figure 3. In each group, with the exception of
group IV, atrial peptide resulted in a significant increase in
inulin clearance as compared to baseline values. Despite this
increase, the differences in GFR values between the groups
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Fig. 4. Urine flow in four grOups (f rats after unilateral release of
bilateral ureteral obstruct ion. Values are given for the baseline period
after release of obstrucdon and each point relresents the mean of 3
clearance periods in eleven rats—group 1(Q). or each of 6 rats, group
II (U). group III (A) or group IV (7). Rates are shown also (closed
symbols) for urine flow during the administration of AP. In each
instance, a marked increase in urine flow was seen in rats of all groups
after administration of AP. A significant difference in baseline urine
flow between rats of groups Ill and IV and those of groups I and II was
observed. These differences in urine flow persisted after infusion of AP.
No significant differences in urine flow, either in the basal state or after
infusion of atrial peptide, were observed between rats, when comparing
values of rats in group I vs. II or rats of group Ill vs. IV.
kg body wt) was observed in rats that had been pretreated with
Enalapril (group III). These values for C in a postobstructed
kidney are indistinguishable from those seen in animals that did
not undergo obstruction. The values, however, are lower than
those seen in normal animals given atrial peptide under those
conditions. Values for such animals in our laboratory averaged
approximately 8.0 ml 0.6 mI/mm/kg body wt.
Figure 4 shows the values for urine flow in the four groups of
rats with unilateral release of BUO before and after administra-
tion of atrial peptide. Of note is the fact that the animals of
groups III and IV had significantly higher values for urine flow
during the basal state than rats of groups IA and II. Infusion of
Fig. 5. The absolute excretion of sodiu,n and the fractional excretion
of sodium in four groups of rats qfter unilateral release of bilateral
ureteral obstruction of 24 hours duration. The absolute sodium excre-
tion (A). both in the basal state and after infusion of AP was significuntly
greater in rats of groups 111 (A) and IV (7) than in rats of groups 1(Q)
and II (LI). In all groups. AP administration markedly increased
absolute sodium excretion. However, the difference in absolute sodium
excretion between groups Ill and IV as compared to groups I and II
persisted. There were no significant differences in absolute sodium
excretion either in the baseline state or after infusion of AP between
groups I and II or between group III vs. group IV. B. The fractional
excretion of sodium during baseline studies and after the infusion of AP
in the same four groups of rats. In three of the four groups administra-
tion of atrial peptide increased fractional sodium excretion. By con-
trast, in group 111 (pretreated with an angiotensin-converting enzyme
inhibitor) AP did not increase fractional sodium excretion.
atrial peptide resulted in a remarkable and significant increase
in urine flow in the four groups, but the urine flow rates in
groups II and IV markedly exceeded those seen in animals of
groups IA and II after the infusion of atrial peptide.
Figure 5 depicts the values for absolute and fractional sodium
excretion, before and after infusion of atrial peptide in the four
groups of rats with unilateral release of BUO. Absolute sodium
excretion in the basal state was significantly greater in rats of
groups III and IV than in rats of groups I and II. Atrial peptide
infusion significantly increased the absolute excretion of so-
dium in all groups. However, the excretion of sodium during
atrial peptide administration was still greater in rats of groups
III and IV than in rats of groups IA and II. On the other hand.
fractional sodium excretion during atrial peptide administration
increased in rats of groups IA. II and IV, but not in rats of group
Ill.
Discussion
The changes in renal blood flow and GFR [5—7] that are
observed after release of obstruction may be mediated in part
by three vasoactive hormone systems acting locally in the
kidney. These systems. renin-angiotensin, prostaglandin-throm-
boxane and kalikrein-kinin, produce vasoactive hormones that
may either increase (prostaglandin E2, prostacycline and kinins)
or decrease (angiotensin II, thromboxane A2) renal blood flow
and GFR [13]. Each of the effector hormones of these three
systems not only has direct effects on the renal vasculature, but
can also affect the level of activity of each of the other two
systems. The present experiments have examined the role of
the renin-angiotensin system and the thromboxane A2 system in
the changes in renal blood flow and GFR that occur after
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unilateral release of bilateral ureteral obstruction in the rat. The
studies clearly demonstrate that blockade of either thrombox-
ane synthesis or angiotensin generation prior to the onset of
obstruction in rats results in a marked and significant increase in
the clearances of inulin and para-aminohippurate, which were
used as measures of glomerular filtration rate and renal plasma
flow. A significant increase in GFR (Fig. 2) was observed in rats
pretreated with inhibitors of thromboxane synthesis (OKY-046)
or with inhibitors of angiotensin converting enzyme (Enalapril).
When the two drugs were used in combination, a greater
increase in GFR was observed than when each drug was used
alone. This suggests that both thromboxane A2 and angiotensin
II participate in the decrease in GFR and renal plasma flow
observed after release of obstruction of 24 hours duration.
Although previous studies have examined the effects of block-
ade of angiotensin II production and of thromboxane synthesis
on renal function of the postobstructed kidney, most of these
studies have utilized intraarterial infusion of the inhibitors after
release of unilateral obstruction [7—9]. In the study in which the
inhibitor of thromboxane synthesis was administered intrave-
nously after release of unilateral ureteral obstruction [9] no
effect on renal hemodynamics was observed. The results of the
present studies demonstrate an increase in GFR and renal
plasma flow after inhibition of thromboxane synthesis or angio-
tensin II generation. However, the increments in GFR and renal
plasma flow observed with acute infusion of the inhibitor after
unilateral release of bilateral ureteral obstruction were quanti-
tatively less than those observed when the rats were pretreated
with the inhibitors of thromboxane synthesis or angiotensin
generation prior to the onset of obstruction. It is possible that
administration of inhibitors of thromboxane synthesis and/or
inhibitors of angiotensin converting enzyme may not com-
pletely inhibit the effects of increased production of these
substances during the 24 hour period of obstruction. In the
present experiments we have eliminated the contribution of
these vasoconstrictors during obstruction by pretreatment of
the animals with the inhibitors of either thromboxane synthesis
or angiotensin synthesis for 48 hours prior to the onset of
obstruction. Under these conditions, one would expect that the
levels of angiotensin II or thromboxane A, would increase
minimally, if at all, during the period of obstruction, hence
binding of these compounds to structures such as vessels,
mesangial cells, etc., during the period of obstruction may not
have occurred. By contrast, in the studies in which the drugs
were administered after the release of obstruction, it is possible
that the effects of already-bound vasoactive compounds could
not be eliminated by pharmacological manipulation at this time.
This presumably was avoided in the experiments in which the
rats were pretreated with OKY-046 or Enalapril prior to the
onset of obstruction. Of note is the fact that the increases in
GFR and renal plasma flow observed with pretreatment were
quantitatively greater than those observed in the experiments in
which the inhibitors were administered after release of obstruc-
tion. The quantitative differences observed when the inhibitors
were administered before or after the onset of obstruction
suggest a much greater contribution of increased production of
angiotensin H and thromboxane A2 to the marked decrease in
GFR and renal plasma flow observed after obstruction of 24
hours duration. Indeed, the combined administration of angio-
tensin Il-converting enzyme inhibitors and inhibitors of throm-
boxane synthesis (group IV of the present study) resulted in
almost complete normalization of GFR in these rats. The values
were not significantly different from values observed in animals
in which manipulation of both ureters without ligation was
accomplished 24 hours prior to obstruction and in which renal
function was measured for one kidney. In these animals
(N = 4), inulin clearance averaged 4.83 mllminlkg body
wt, a value not significantly different from the mean value of
5.93 0.53 mI/mm/kg body wt obtained in rats that had
unilateral release of bilateral ureteral obstruction after pretreat-
ment with both OKY-046 and Enalapril. This value also is not
significantly different from the mean inulin value of 5.82 0.20
ml! mm kg body wt obtained for one kidney in normal rats (Fig.
1). Whether the use of angiotensin Il-converting enzyme inhib-
itors and the effects of this maneuver on GFR relate only to
decreased production of angiotensin II, to increase generation
of kinins or to both effects cannot be discerned from the present
data. Additional experiments examining the effects of blockade
of kinin production in animals in which angiotensin H has been
inhibited may help to delineate the relative contributions of
inhibition of angiotensin II per se from that of increased
synthesis of kinin resulting from blockade of angiotensin con-
verting enzyme.
The present studies also examined the effects of infusion of
atrial peptide on renal hemodynamics in rats in which angioten-
sin II and thromboxane synthesis had or had not been inhibited,
Of interest in this respect is our finding that after unilateral
release of bilateral ureteral obstruction, administration of atrial
peptide increased GFR, urine flow and absolute sodium excre-
tion.
The mechanisms by which atrial peptide exerts its renal
effects have been studied, although controversy remains on the
precise sites of action of the hormone and subsequent steps by
which it influences cellular function [14—20].
Interactions of atrial peptide with other hormones have been
described especially with the renin-angiotensin-aldosterone
system [16, 21—23]. Atrial peptide antagonizes the smooth
muscle contraction induced by norepinephrine and angiotensin
[24, 25]. In the isolated perfused kidney, increased vascular
resistance induced by norepinephrine, vasopressin or angioten-
sin II is attenuated by AP [26]. In the present studies atrial
peptide administration increased GFR both in the presence and
"absence" of the vasoconstrictors thromboxane A2 and angio-
tensin II.
Previous experiments have demonstrated that administration
of AP can result in an increase in GFR in the remnant kidney of
the rat, a setting in which single nephron GFR is already
increased [27]. Since both the total number of filtering nephrons
and single nephron GFR are decreased after release of ureteral
obstruction [10, 11, 28], the mechanisms of the increased whole
kidney GFR during AP administration may relate to both an
increase in single nephron GFR and a recruitment of additional
filtering nephrons.
The role that AP may play in the hemodynamic changes
which occur with obstruction have not been characterized. The
present studies examine the effects of exogenous infusion of
atrial peptide on glomerular filtration and on sodium and water
excretion after unilateral release of BUO of 24 hours duration.
Of note was the fact that in each of the groups, with exception
of the animals that received both Enalapril and OKY-046 (group
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IV). AP administration resulted in a marked increase in GFR as
compared to the values obtained during the baseline periods in
the same animals. It is also remarkable that AP administration
increased GFR in animals of group I which were not pretreated.
Increments in GFR were also observed in animals that received
inhibitors of thromboxane synthesis and/or angiotensin II,
suggesting that the effect of atrial peptide on GFR can be
dissociated from an action involving just antagonism of the
effect of these vasoconstrictors.
Of interest in the present studies is the finding that adminis-
tration of AP increased absolute and fractional sodium excre-
tion in the postobstructed kidney of rats with BUO. It has been
shown that in this model of obstruction the renal medullary
gradient has been dissipated [llJ. Hence, a diuretic effect of AP
in this setting can hardly be attributed to further dissipation of
the medullary gradient. The increase in fractional sodium
excretion observed during AP administration suggests that
increases in the filtered load of sodium alone, without a change
in sodium reabsorption, may not be sufficient to explain the
natriuresis which occurred in the postobstructed kidney when
the hormone was given. Consequently, we would suggest that
after release of obstruction the natriuresis observed during
administration of AP may be due not only to an increased
filtered load of sodium but also to decreased tubular reabsorp-
tion of sodium, perhaps at distal segments. It is of interest that
in rats which received the inhibitor of angiotensin converting
enzyme the administration of AP increased the absolute excre-
tion of sodium but not its fractional excretion. This suggests
that AP may decrease tubular reabsorption of sodium by
antagonizing the effect of angiotensin on sodium reabsorption
[29, 30].
In summary, the results of the present studies suggest that the
vasoconstrictors angiotensin II and thromboxane A2 have a
major role in the decrease of GFR observed after unilateral
release of bilateral ureteral obstruction. They also indicate that
AP can increase GFR in the postobstructed kidney both in the
presence or absence of "normal" synthesis of angiotensin II
and thromboxane A2. This suggests a potential role for atrial
peptide in modulating renal hemodynamics in the postobstruc-
ted kidney of rats with bilateral ureteral obstruction.
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